Document Type


Publication Date



This article has been peer reviewed. It is the author’s final published version in Scientific World Journal Volume 2014, Article number 869604.

The published version is available at DOI: 10.1155/2014/869604. Copyright © Hindawi Publishing Corporation


The tools for managing retinoblastoma have been increasing in the past decade. While globe-salvage still relies heavily on intravenous chemotherapy, tumors in advanced stage that failed chemotherapy are now referred for intra-arterial chemotherapy (IAC) to avoid enucleation. However, IAC still has many obstacles to overcome. We present an update on the indications, complications, limitations, success, and technical aspects of IAC. Given its safety and high efficacy, it is expected that IAC will replace conventional strategies and will become a first-line option even for tumors that are amenable for other strategies.